Next Article in Journal
Liquid and Vapor Phase of Four Conifer-Derived Essential Oils: Comparison of Chemical Compositions and Antimicrobial and Antioxidant Properties
Next Article in Special Issue
Deciphering the H-Bonding Preference on Nucleoside Molecular Recognition through Model Copper(II) Compounds
Previous Article in Journal
Development of Controlled-Release Carbamide Peroxide Loaded Nanoemulgel for Tooth Bleaching: In Vitro and Ex Vivo Studies
Previous Article in Special Issue
Mercury Toxicity and Detection Using Chromo-Fluorogenic Chemosensors

Monofunctional Platinum(II) Anticancer Agents

by 1,†, 1,2,†, 1 and 3,*
State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China
School of Materials and Chemical Engineering, Henan University of Urban Construction, Pingdingshan 467036, China
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China
Author to whom correspondence should be addressed.
These authors contributed equally to this article.
Academic Editor: Guido Crisponi
Pharmaceuticals 2021, 14(2), 133;
Received: 12 January 2021 / Revised: 2 February 2021 / Accepted: 4 February 2021 / Published: 7 February 2021
(This article belongs to the Special Issue Applications of Medicinal Bioinorganic Chemistry)
Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]+ (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs. View Full-Text
Keywords: anticancer drug; drug design; metal-based drug; monofunctional platinum complex anticancer drug; drug design; metal-based drug; monofunctional platinum complex
Show Figures

Figure 1

MDPI and ACS Style

Jin, S.; Guo, Y.; Guo, Z.; Wang, X. Monofunctional Platinum(II) Anticancer Agents. Pharmaceuticals 2021, 14, 133.

AMA Style

Jin S, Guo Y, Guo Z, Wang X. Monofunctional Platinum(II) Anticancer Agents. Pharmaceuticals. 2021; 14(2):133.

Chicago/Turabian Style

Jin, Suxing, Yan Guo, Zijian Guo, and Xiaoyong Wang. 2021. "Monofunctional Platinum(II) Anticancer Agents" Pharmaceuticals 14, no. 2: 133.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop